Alzheimer's disease (AD) is well-known as a severe neurodegeneration disease involving
complicated etiologies, and cholinesterase inhibition remain the prevailing mode of clinical …

Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …

Neuroinflammation and cholinergic dysfunction, leading to cognitive impairment, are
hallmarks of aging and neurodegenerative disorders, including Alzheimer's disease (AD) …

Background The mainstay of therapy for many neurodegenerative dementias still relies on
acetylcholinesterase inhibitors (AChEI); however, there is debate on various aspects of such …

Dementia is a syndrome of global and progressive deterioration of cognitive skills,
especially memory, learning, abstract thinking, and orientation, usually affecting the elderly …

Background: While the angiotensin-converting enzyme degrades amyloid-β,
angiotensinconverting enzyme inhibitors (ACEis) may slow cognitive decline by way of …

The α7 nicotinic acetylcholine receptor (CHRNA7) modulates the inflammatory response by
activating the cholinergic anti-inflammatory pathway. CHRFAM7A, the human-restricted …

The development of Alzheimer's disease therapeutics has been challenging, with 99% of
clinical trials failing to find a significant difference between drug and placebo. While the …

The practical pharmacogenetics of Alzheimer's disease (AD) is circumscribed to
acetylcholinesterase inhibitors (AChEIs) and memantine. However, pharmacogenetic …

Genetic variations in individuals may cause differences in the response to cholinesterase
inhibitor drugs used in the treatment of Alzheimer's disease (AD). Through this review, we …